Results from a phase I study (NCT03289455) with bicistronic CD19/CD22 bispecific CAR-T cells for the treatment of 15 patients with r/r B-ALL showed 86% CR and one-year overall survival and event-free survival of 60% and 32%, respectively (139). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.